Table 1 Clinical characteristics of the patient at baseline and during dupilumab treatment (with concomitant medications)

EASI score (scale 0–72)

29

12.5

4.6

4

4

SCORAD-total score (scale 0–103)

78

40.9

45.5

20

16

IGA score (scale 0–4)

4

3

3

2

2

NRS pruritus score (scale 0–10)

8

3

8

2

1

NRS sleep score (scale 0–10)

9

1

8

1

1

POEM score (scale 0–30)

21

2

20

2

2

DLQI score (scale 0–28)

13

15

7

1

1

FEV1 (L)

2.60

2.48

2.5

2.5

2.72

FEV1 (% predicted)

89.4%

84%

85%

85%

93.3%

ACT score (scale 0–25)

21

24

25

25

25

ACQ-5 score (scale 0–6)

0.9

0.7

0.1

0.0

0.0

AQLQ score (scale 0–7)

6.3

6.6

6.8

6.7

6.7

Bilateral ENPS (scale 0–8)

3

–

–

–

0

SNOT-22 score (scale 0–110)

20

14

12

15

11

Loss of smell score (scale 0–3)

2

2

1

1

1

Rhinitis disease severity (visual analog scale 0–10 cm)

6

5

3

3

2

RQLQ (scale 0–6)

2.85

2.64

2.51

2.64

2.31

Total IgE levels, KUA/L

1633 kUA/L

–

–

–

901.8 kUA/L

Blood eosinophil Count, cells/μ

239/mm3

–

–

–

50/mm3

Concomitant medications

Clobetasol proprionate oinment 0.05%, 2 times a day;

Desloratadine 5 mg/die;

Beclomethasone/formoterol fumarate (200/6 μg)two inhalations twice daily

Desloratadine 5 mg as needed; Beclomethasone/formoterol fumarate (200/6 μg) one inhalation twice daily

Desloratadine 5 mg as needed; Beclomethasone/formoterol fumarate (100/6 μg) one inhalation twice daily

Beclomethasone/formoterol fumarate (100/6 μg) one inhalation twice daily

Beclomethasone/formoterol fumarate (100/6 μg) one inhalation as needed